CD274 and hepatocellular carcinoma: Furthermore, progress has been made in the application of ICB in HCC, such as anti-CTLA-4, anti-PD-1/PD-L1, a combination of both, and immune checkpoint inhibitors combined with surgical resection, multikinase inhibitors, chemotherapy, or local area therapies95–98.